Friedrich-Alexander Ludwig

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/4482565/publications.pdf

Version: 2024-02-01

1039406 996533 28 252 9 15 citations h-index g-index papers 28 28 28 383 docs citations times ranked citing authors all docs

#	Article	IF	CITATIONS
1	Synthesis of Natural Product Precursors by Baeyer-Villiger Oxidation with Cyclohexanone Monooxygenase from Acinetobacter. Synthesis, 2001, 2001, 0947-0951.	1.2	43
2	<i>N</i> ^ε -Acryloyllysine Piperazides as Irreversible Inhibitors of Transglutaminase 2: Synthesis, Structure–Activity Relationships, and Pharmacokinetic Profiling. Journal of Medicinal Chemistry, 2018, 61, 4528-4560.	2.9	27
3	Improved in vivo PET imaging of the adenosine A2A receptor in the brain using [18F]FLUDA, a deuterated radiotracer with high metabolic stability. European Journal of Nuclear Medicine and Molecular Imaging, 2021, 48, 2727-2736.	3.3	18
4	Development of a Novel Nonpeptidic ¹⁸ F-Labeled Radiotracer for in Vivo Imaging of Oxytocin Receptors with Positron Emission Tomography. Journal of Medicinal Chemistry, 2016, 59, 1800-1817.	2.9	17
5	Development of a New Radiofluorinated Quinoline Analog for PET Imaging of Phosphodiesterase 5 (PDE5) in Brain. Pharmaceuticals, 2016, 9, 22.	1.7	15
6	Targeting cyclic nucleotide phosphodiesterase 5 (PDE5) in brain: Toward the development of a PET radioligand labeled with fluorine-18. Bioorganic Chemistry, 2019, 86, 346-362.	2.0	14
7	LC-MS Supported Studies on the in Vitro Metabolism of both Enantiomers of Flubatine and the in Vivo Metabolism of (+)-[18F]Flubatine—A Positron Emission Tomography Radioligand for Imaging α4β2 Nicotinic Acetylcholine Receptors. Molecules, 2016, 21, 1200.	1.7	12
8	Comparison of inâ \in Silico, Electrochemical, inâ \in Vitro and inâ \in Vivo Metabolism of a Homologous Series of (Radio)fluorinated $\ddot{l}f$ < sub>1 Receptor Ligands Designed for Positron Emission Tomography. ChemMedChem, 2016, 11, 2445-2458.	1.6	12
9	(+)-[18F]Flubatine as a novel α4β2 nicotinic acetylcholine receptor PET ligand—results of the first-in-human brain imaging application in patients with β-amyloid PET-confirmed Alzheimer's disease and healthy controls. European Journal of Nuclear Medicine and Molecular Imaging, 2021, 48, 731-746.	3.3	10
10	Exploring the Metabolism of (+)-[18F]Flubatine In Vitro and In Vivo: LC-MS/MS Aided Identification of Radiometabolites in a Clinical PET Study â€. Molecules, 2018, 23, 464.	1.7	9
11	In vitro and in vivo Human Metabolism of (S)-[18F]Fluspidine – A Radioligand for Imaging σ1 Receptors With Positron Emission Tomography (PET). Frontiers in Pharmacology, 2019, 10, 534.	1.6	9
12	Synthesis and In Vitro Evaluation of 8-Pyridinyl-Substituted Benzo[e]imidazo[2,1-c][1,2,4]triazines as Phosphodiesterase 2A Inhibitors. Molecules, 2019, 24, 2791.	1.7	9
13	Role of TRPC6 in kidney damage after acute ischemic kidney injury. Scientific Reports, 2022, 12, 3038.	1.6	7
14	Radiosynthesis of (S)-[18 F] T1: The first PET radioligand for molecular imaging of $\hat{l}\pm3\hat{l}^24$ nicotinic acetylcholine receptors. Applied Radiation and Isotopes, 2017, 124, 106-113.	0.7	6
15	Development and radiosynthesis of the first ¹⁸ Fâ€kabeled inhibitor of monocarboxylate transporters (MCTs). Journal of Labelled Compounds and Radiopharmaceuticals, 2019, 62, 411-424.	0.5	6
16	Design, Radiosynthesis and Preliminary Biological Evaluation in Mice of a Brain-Penetrant 18F-Labelled If 2 Receptor Ligand. International Journal of Molecular Sciences, 2021, 22, 5447.	1.8	6
17	Radiosynthesis and Biological Investigation of a Novel Fluorine-18 Labeled Benzoimidazotriazine- Based Radioligand for the Imaging of Phosphodiesterase 2A with Positron Emission Tomography. Molecules, 2019, 24, 4149.	1.7	5
18	Sigma-1 Receptor Positron Emission Tomography: A New Molecular Imaging Approach Using (S)-(â^')-[18F]Fluspidine in Glioblastoma. Molecules, 2020, 25, 2170.	1.7	5

#	Article	IF	CITATIONS
19	Development of 18F-Labeled Radiotracers for PET Imaging of the Adenosine A2A Receptor: Synthesis, Radiolabeling and Preliminary Biological Evaluation. International Journal of Molecular Sciences, 2021, 22, 2285.	1.8	5
20	Development of Novel Analogs of the Monocarboxylate Transporter Ligand FACH and Biological Validation of One Potential Radiotracer for Positron Emission Tomography (PET) Imaging. Molecules, 2020, 25, 2309.	1.7	4
21	Development of fluorinated and methoxylated benzothiazole derivatives as highly potent and selective cannabinoid CB2 receptor ligands. Bioorganic Chemistry, 2021, 114, 105191.	2.0	4
22	Preclinical Incorporation Dosimetry of [18F]FACHâ€"A Novel 18F-Labeled MCT1/MCT4 Lactate Transporter Inhibitor for Imaging Cancer Metabolism with PET. Molecules, 2020, 25, 2024.	1.7	3
23	Validation of an LC-MS/MS Method to Quantify the New TRPC6 Inhibitor SH045 (Larixyl) Tj ETQq1 1 0.784314 rg Pharmaceuticals, 2021, 14, 259.	gBT /Overl 1.7	ock 10 Tf 50 3
24	Asymmetric Synthesis of Spirocyclic 2-Benzopyrans for Positron Emission Tomography of $If 1$ Receptors in the Brain. Pharmaceuticals, 2014, 7, 78-112.	1.7	2
25	Structure $\hat{a} \in \text{``Affinity Relationships of Fluorinated Spirocyclic \"{i}f}$ 2 Receptor Ligands with an Exocyclic Benzylamino Moiety. ChemMedChem, 2019, 14, 1392-1402.	1.6	1
26	Preclinical Evaluation of [18F]FACH in Healthy Mice and Piglets: An 18F-Labeled Ligand for Imaging of Monocarboxylate Transporters with PET. International Journal of Molecular Sciences, 2021, 22, 1645.	1.8	0
27	Development and Biological Evaluation of the First Highly Potent and Specific Benzamide-Based Radiotracer [18F]BA3 for Imaging of Histone Deacetylases 1 and 2 in Brain. Pharmaceuticals, 2022, 15, 324.	1.7	0
28	A Pharmacokinetic and Metabolism Study of the TRPC6 Inhibitor SH045 in Mice by LC-MS/MS. International Journal of Molecular Sciences, 2022, 23, 3635.	1.8	0